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Abstract
Both genetic and environmental factors interact to control left ventricular (LV) remodeling in the context of aortic stenosis 
(AS). Epicardial adipose tissue (EAT) is a specific visceral adipose tissue with paracrine properties in close contact with the 
myocardium. We sought to assess determinants of EAT amount and its association with the magnitude and pattern of LV 
remodeling in patients suffering from severe AS. Between January 2014 and September 2017, we prospectively explored 
consecutive patients referred to our Heart Valve Center for SAVR presenting with severe AS and normal left ventricular 
ejection fraction (> 50%). Comprehensive transthoracic echocardiography (TTE) including assessment of LV remodeling 
and EAT amount were performed. 202 patients were included. EAT was significantly larger in elderly, diabetic and obese 
patients. EAT thickness was correlated positively with indexed LV mass in AS  (r2 = 0.21; p < 0.0001) as well as severe LV 
remodeling pattern. Importantly, this observation persisted after adjustment for other factors associated with LV remodeling 
(β ± SE = 1.74 ± 0.34; p < 0.0001). Large amounts of EAT are positively and independently associated with more pronounced 
and severe LV remodeling in severe AS. Further exploration regarding the impact of functional properties of EAT on LV 
remodeling is required.
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Introduction
In patients with aortic stenosis (AS), left ventricular hyper-
trophy (LVH) develops as a response to chronic pressure 
overload. This ventricular remodeling is primarily adaptive, 
reducing wall stress and preserving systolic cardiac function. 
Yet, LVH initiates a vicious circle leading to diastolic dys-
function, myocardial fibrosis, dilation, and finally heart fail-
ure [1]. Accordingly, LVH is associated with increased risk 
of cardiac events and poor prognosis in AS before and after 
surgical aortic valve replacement (SAVR) [2–4].
Genetic and environmental factors interact with the LV 
remodeling process in AS. Several studies reported these 
past few years that obesity, the metabolic syndrome, and type 
2 diabetes are associated with more pronounced LVH [5–7]. Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1055 4-018-1477-z) contains 
supplementary material, which is available to authorized users.
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However, the nature of the link between these metabolic 
disorders and cardiac remodeling is still poorly understood.
Visceral adipose tissue is a major source of adipokines 
and cytokines promoting insulin resistance and cardiovas-
cular disorders in obese and diabetic patients [8]. Epicardial 
adipose tissue (EAT) is a visceral adipose tissue in close 
contact with the myocardium. Being located around the 
heart underneath the visceral pericardial layer, EAT is in 
direct contact with the epicardium [9]. EAT is thus a first-
class candidate to modulate the function of the myocardium 
and coronary vasculature [10].
Interestingly, EAT amount and its secretory/paracrine 
properties are altered in both obesity and type 2 diabetes [8, 
11]. Moreover, visceral adipose tissue amount is indepen-
dently associated with indexed left ventricular mass (LVMi) 
in patients with moderate AS [12].
Nevertheless, to our knowledge, there is no study on the 
specific association between EAT and ventricular remod-
eling in AS.
In the present study, we hypothesized that increased EAT 
amount is associated with poorer LV remodeling in AS.
Methods
Study population and design
From January 2014 to September 2017, we prospectively 
studied consecutive patients with severe AS referred to our 
Heart Valve Center (CHU Lille) for SAVR. Patients with 
reduced left ventricular ejection fraction (< 50%) were 
excluded to get a homogeneous population. Patients with 
another significant valvular disease, a medical history of 
previous cardiac surgery or congenital heart disease were 
also excluded.
The local ethics committee approved the protocol and 
patients gave informed consent.
Cardiac imaging
A comprehensive transthoracic echocardiography (TTE) was 
performed in all patients before after cardiac surgery using a 
commercially available ultrasound machine (Vivid E9, GE 
Healthcare, Little Chalfont, UK) and stored for off-line anal-
ysis (EchoPAC version 201.0.0; GE Vingmed Ultrasound, 
Horten, Norway). All measures were performed according 
to current guidelines, particularly for the assessment of AS, 
and LV structure and function [13].
LV remodeling assessment
LV mass was calculated using M-mode recordings accord-
ing to the American Society of Echocardiography and the 
European Association of Cardiovascular Imaging [13, 14]. 
LV mass was indexed to body height in the allometric power 
of 2.7 to get indexed LV mass (LVMi) [15]. LV hypertro-
phy (LVH) was defined using the common cutoff values, 
i.e. LVMi > 46.7 g/m2.7 in women and > 49.2 g/m2.7 in men.
Relative wall thickness (RWT) was calculated from TTE 
measures as the following ratio: (2 × LV posterior wall thick-
ness/LV end diastolic diameter).
Considering both LVMi and RWT, patients were classi-
fied as having one of the 4 LV remodeling patterns using the 
following criteria: (1) normal pattern: absence of LVH and 
RWT < 0.42; (2) concentric remodeling: absence of LVH 
and RWT ≥ 0.42; (3) concentric hypertrophy: presence of 
LVH and RWT ≥ 0.42; and (4) eccentric hypertrophy: pres-
ence of LVH and RWT < 0.42.
Epicardial adipose tissue assessment
EAT was measured as the echo-free space between the outer 
wall of the myocardium and the visceral layer of the pericar-
dium with TTE. EAT thickness was measured off-line with 
EchoPac (GE Healthcare), perpendicularly to the free wall 
of the right ventricle at end-systole in 3 cardiac cycles in 
the parasternal long-axis view as previously described [16]. 
Inter-observer reproducibility for this measurement was high 
with intraclass correlation coefficient of 0.93 IC [0.88; 0.96].
To further validate this method, EAT amounts were com-
pared between TTE and cardiac magnetic resonance (CMR) 
in 84 patients explored for a LVH. The correlation between 
these two techniques was good in our center (r = 0.64, 
p = 0.0001) (Supplemental Fig. 1).
Statistical analysis
Statistics were performed with MedCalc v16.4 (Olstead, 
Belgium). Continuous variables were tested for normality 
with Shapiro test, and are given as mean ± SD. t-test and 
linear regression were performed for bi-variate analysis. 
Categorical variables are given as the number (percentage) 
of patients with the respective attribute and compared with 
Chi-square test.
Pearson correlation was used to explore the link between 
EAT thickness and LVMi. Chi-square for trend was used to 
assess relations between EAT amount and LV remodeling 
patterns, patients being divided on EAT thickness median. 
Multivariable linear regression analysis was performed to 
identify variables independently associated with LVMi. 
Variables with a p value < 0.10 on univariable analysis were 
entered into the multivariable models.
A value of p < 0.05 was considered statistically signifi-
cant. Figures were drawn with GraphPad Prism version 5.0.
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Results
A total of 202 patients referred for a first SAVR were 
included. Patients’ characteristics are summarized in 
Table 1. Mean age was 69 ± 10 years. The population was 
made of 62% of male and a third had diabetes. 79% of 
them were overweight (43%) or obese (36%). Regarding 
medications, half of the patients was treated with beta-
blockers or ACE inhibitors/ARBs.
EAT amount was larger in older (p = 0.0063), hyper-
tensive (p = 0.016) and diabetic patients (p < 0.0001) with 
higher BMI (p < 0.0001) in bi-variate analysis (Table 2). 
Conversely, gender was not associated with EAT thick-
ness. After adjustment by multilinear regression, older age 
(p = 0.01), higher BMI (p < 0.0001) and diabetes mellitus 
(p = 0.008) remained significantly associated with larger 
EAT amount.
After splitting the population in half according to 
LVMi median, patients with higher LVMi had higher BMI 
Table 1  Patients’ characteristics 
(n = 202)
Bold value represents p < 0.05 between Low LVMi and High LVMi
ACE angiotensin-converting enzyme; Ao aortic; ARBs Angiotensin II receptor blockers; BMI body mass 
index; EAT epicardial adipose tissue; iEOA indexed effective orifice area; LA left atrium; LVEF left ven-
tricular ejection fraction; LVMi left ventricular mass index; NYHA New York Heart Association; ZVA val-
vuloarterial impedance






 Age (years) 68.8 ± 9.7 67.9 ± 10.4 69.6 ± 9.0 0.22
 Gender (male) n (%) 125 (61.9) 67 (65.7) 58 (58.0) 0.26
 BMI (kg/m2) 28.9 ± 4.9 27.8 ± 4.6 29.9 ± 4.9 0.002
 Normal n (%) 43 (21.3) 31 (30.4) 12 (12.0) 0.001
 Overweight n (%) 87 (43.1) 44 (43.1) 43 (43.0) 0.98
 Obese n (%) 72 (35.6) 27 (26.5) 45 (45.0) 0.006
 Hypertension n (%) 148 (73.3) 74 (72.5) 74 (74.0) 0.82
 Diabetes mellitus n (%) 72 (35.6) 26 (25.5) 46 (46.0) 0.002
 Smoking n (%) 55 (27.2) 25 (24.5) 30 (30.0) 0.38
 NYHA class 2.09 ± 0.7 2.09 ± 0.7 2.10 ± 0.7 0.97
 Class I n (%) 5 (2.5) 1 (1.0) 4 (4.0)
 Class II n (%) 23 (11.4) 15 (14.7) 8 (8.0)
 Class III n (%) 122 (60.4) 60 (58.9) 62 (62.0)
 Class IV n (%) 52 (25.7) 26 (25.5) 26 (26.0)
 Euroscore 2 (%) 1.50 [1.05; 2.30] 1.41 [0.97; 2.20] 1.53 [1.13; 2.44] 0.10
Treatments
 Beta-blockers n (%) 71 (35.1) 33 (32.4) 38 (38.0) 0.40
 ACE inhibitors/ARBs n (%) 100 (49.5) 50 (49.0) 50 (50.0) 0.89
 Oral anti diabetic n (%) 71 (35.1) 26 (25.5) 45 (45.0) 0.004
 Insulin therapy n (%) 21 (10.4) 5 (4.9) 16 (16.0) 0.01
Biology
 NT-pro-BNP (ng/l) 396 [180; 1052] 367 [158; 718] 401 [236; 1455] 0.17
 Creatinine (mg/l) 9.0 [8.0; 10.3] 9.0 [8.0; 10.1] 9.0 [7.7; 10.9] 0.19
Cockroft et Gault (ml/min) 79.5 [67.0; 98.0] 81.0 [68.0; 99.3] 78.0 [63.5; 93.0] 0.37
Cardiac imaging
 Peak Ao velocity (m/s) 4.40 [4.14; 4.79] 4.39 [4.14; 4.60] 4.50 [4.15; 4.90] 0.07
 Mean Ao gradient (mmHg) 50.5 [42.5; 60.3] 50.0 [42.0; 55.1] 52.0 [43.9; 63.8] 0.01
 iEOA  (cm2/m2) 0.34 [0.29; 0.42] 0.34 [0.30; 0.42] 0.35 [0.29; 0.42] 0.95
 LVEF (%) 61.3 ± 9.3 62.3 ± 7.2 60.2 ± 35.7 0.11
 LA area  (cm2) 24.5 ± 8.0 23.1 ± 5.7 25.9 ± 9.7 0.01
 ZVA (mmHg/ml/m2) 5.1 [4.2; 6.1] 5.1 [4.3; 6.0] 5.1 [4.1; 6.5] 0.59
 LVMi (g/m2,7) 54.9 ± 14.1 44.0 ± 6.9 66.1 ± 10.4 < 0.0001
 EAT thickness (mm) 6.9 ± 3.0 5.7 ± 2.4 8.1 ± 3.1 < 0.0001
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(29.9 ± 4.9 vs. 27.8 ± 4.6 kg/m2, p = 0.002), were more fre-
quently diabetic (46 vs. 25%, 0.002), with higher mean 
aortic gradient (52.0 [43.9; 63.8] vs. 50.0 [42.0; 55.1] 
mmHg, p = 0.01) and higher EAT thickness (8.1 ± 3.1 
vs; 5.7 ± 2.4 mm, p < 0.001). This minimal difference 
between mean aortic gradient can be merely due to inter/
intra-observer variability and suggest that other factors can 
impact LV remodeling in AS.
We next explored the link between EAT amount and 
LVMi, an index of LV remodeling magnitude. Interest-
ingly, LVMi correlated positively with EAT thickness 
 (r2 = 0.21, p < 0.0001) (Fig. 1). This association between 
EAT thickness and LVMi remained significant even after 
adjustment for other determinants of LVMi (Table 3). 
Overall the results were the same whatever the normali-
zation of the LVM (Supplemental Table 1).
To further evaluate the link between LV remodeling and 
EAT, we explored whether EAT amount correlated with pat-
terns of LV remodeling.
Very few patients (20; 9.9%) displayed an absence of 
remodeling. 52 (25.7%) patients had concentric LV remode-
ling, 104 (51.5%) concentric LV hypertrophy and 26 (12.9%) 
eccentric LV hypertrophy. Interestingly, the magnitude of 
LV remodeling was associated with EAT amount (p < 0.0001 
by Chi-square for trend; Fig. 2).
Thus, in addition to the association between EAT quan-
tity and LV mass, EAT amount was associated with a more 
severe LV remodeling pattern in AS.
Discussion
Exploring patients suffering from severe AS, we demon-
strate that EAT amount is positively correlated with the 
extent of LVMi and with a more pathological remodeling 
pattern. Importantly, this observation persisted even after 
adjustment for other factors associated with LV remodeling.
EAT, clinical metabolic disorders, and LV remodeling
The human heart is coated with fat, which is in direct 
contact with the epicardium and is a source of free fatty 
acids, adipokines, and inflammatory cytokines [17]. Shar-
ing a common microcirculation with the myocardium, 
EAT is believed to directly interact with cardiomyocytes 
in both physiology and pathology through paracrine sign-
aling. Growing evidence supports this paradigm. On the 
one hand, EAT amount and quality have been shown to be 
altered by aging and metabolic disorders associated with 
high incidence of cardiovascular disease (CVD) [18, 19]. 
On the other hand, epidemiological studies demonstrated a 
Table 2  Determinants of 
epicardial adipose tissue 
thickness (n = 202)
Bold value represents p < 0.05 between Low LVMi and High LVMi
p-value by t-test or linear regression in bivariate analysis. Regression coefficient, standard errors and 
p-value from multivariate linear regression model constructed with all variables with p < 0.10 in bivariate 
analysis
ACE angiotensin converting enzyme; ARBs angiotensin II receptor blockers; BMI body mass index
Univariable Multivariable
β ± SE p β ± SE p
Gender (male) − 0.69 ± 0.43 0.11
Age (years) 0.06 ± 0.02 0.0063 0.05 ± 0.02 0.0103
BMI (kg/m2) 0.33 ± 0.04 < 0.0001 0.25 ± 0.04 < 0.0001
Diabetes mellitus n (%) 2.01 ± 0.42 < 0.0001 1.07 ± 0.39 0.0083
Hypertension n (%) 1.17 ± 0.46 0.016 – –
Mean aortic gradient (mmHg) − 0.003 ± 0.01 0.84
Beta blockers − 0.43 ± 0.44 0.33
ACE inhibitors/ARBs 0.98 ± 0.46 0.03 – –
Fig. 1  Correlation between EAT amount and LV mass.  r2 and p-value 
by Pearson correlation and drawn line by linear regression
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clear positive correlation between EAT volume and/or pro-
inflammatory phenotype with CVD incidence and severity. 
Large EAT amounts, quantified by TTE [19], CT scan [20] 
or CMR [21], are consistently associated with severe coro-
nary artery disease. Hirata et al. showed that infiltration of 
macrophages in EAT is enhanced in patients with coronary 
artery disease together with a shift of macrophage polariza-
tion toward a pro-inflammatory state, i.e. an increased M1/
M2 macrophage ratio [22]. These results suggested that EAT 
might influence atherogenesis in coronary arteries. In the 
same line, EAT amount and pro-inflammatory activity have 
been shown to be enhanced in atrial fibrillation patients [23].
Regarding EAT and cardiac remodeling, data from a few 
autopsy and echocardiographic studies reporting conflict-
ing data are available. Coradi et al., exploring 117 human 
autopsy hearts, observed a constant ratio in each ventricle 
between EAT weight and muscle weight, even in presence of 
cardiac hypertrophy or features of ischemic cardiomyopathy 
Table 3  Determinants of 
indexed left ventricular mass 
normalized to  height2.7 (n = 202)
Bold value represents p < 0.05 between Low LVMi and High LVMi
p-value by t-test or linear regression in bivariate analysis. Regression coefficient, standard errors and 
p-value from multivariate linear regression model constructed with all variables with p < 0.10 in bivariate 
analysis
BMI body mass index; EAT epicardial adipose tissue; LVEF left ventricular ejection fraction; ZVA valvu-
loarterial impedance
Univariable Multivariable
β ± SE p β ± SE p
Gender (male) − 1.77 ± 2.04 0.38
Age (years) 0.10 ± 0.10 0.33
BMI (kg/m2) 0.84 ± 0.20 < 0.0001 0.19 ± 0.21 0.36
Diabetes mellitus n (%) 6.26 ± 2.03 0.0024 2.08 ± 1.90 0.27
Hypertension n (%) 1.57 ± 2.23 0.48
Mean aortic gradient (mmHg) 21.6 ± 7.8 0.006 0.20 ± 0.06 0.0003
ZVA (mmHg/ml/m2) − 2.87 ± 8.2 0.73
LVEF (%) − 0.15 ± 0.11 0.17
EAT (mm) 2.13 ± 0.29 < 0.0001 1.74 ± 0.34 < 0.0001
Euroscore II (%) 3.18 ± 3.79 0.40
Fig. 2  Patterns of LV remod-
eling according to EAT amount. 
Patients were divided in two 
groups according to EAT thick-
ness median. p-value by Chi- 
square for trend
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[24]. The authors thus suggested that during the hyper-
trophic process, EAT and the ventricles presented a parallel 
and correlated increase in their masses. It is to be underlined 
that the etiology of cardiac hypertrophy was not reported in 
these 60 dead patients classified as having <<hypertrophic 
hearts>>. Exploring 60 lean-to-obese healthy subjects, Iaco-
bellis et al. showed a consistent positive correlation between 
EAT amount and LV mass [25]. Moreover, Capoulade et al. 
found that obesity and excess visceral adiposity (reflected by 
higher visceral adipose tissue/total adipose tissue ratio) were 
independently associated with LVH in 124 patients with AS 
[12]. Taken altogether, our results are consistent with Iaco-
bellis and Capoulade findings and reinforce the concept that 
clinical conditions such as obesity, diabetes and aging may 
alter EAT, which in turn may impact the hypertrophic pro-
cess in patients suffering from AS.
Perspectives
Taken together, our findings indicate that EAT amount is 
associated with the hypertrophic response in AS. Although 
the observational design of our study limits any conclusion 
regarding causality, evidence from basic science strongly 
supports a role for EAT in cardiac disorders observed in 
obesity and diabetes.
Yet, the precise mechanisms by which EAT and myocar-
dium are associated in AS patients remain to be determined. 
Among the numerous adipokines and cytokines secreted by 
EAT, for only a few mechanistic data are available. Increases 
in TNFɑ, IL-10 or IL-6 or decreases in adiponectin sign-
aling interfere with hypertrophic signaling pathways in 
rodent models and in vitro cardiomyocyte cultures [22]. 
Further exploration of the functional properties of EAT in 
the patients suffering from LV remodeling is required. This 
may open avenues for pharmacological strategies to modu-
late EAT activity and as such slow down the progression 
of LV remodeling in AS, specifically in those with obesity 
and diabetes.
Limitations
Our study has several limitations. First, we used a histori-
cal method (M-mode) that may have technical problems 
to calculate LVM compared to the more recent methods, 
including 3D. Second, EAT amount was estimated by meas-
uring EAT thickness with TTE [16]. The linear measurement 
made with TTE on the right ventricular free wall cannot 
perfectly reflect the distribution and amount of EAT cover-
ing the LV. Nerlekar et al. recently found a poor correlation 
between EAT thickness measured by TTE and EAT area/
volume measured by using cardiac computed tomography 
(CT) (r = 0.29) [26]. Nevertheless, the amount of EAT was 
low in their patients evaluated with cardiac CT for suspected 
coronary artery disease. In opposition, we found a good cor-
relation between EAT thickness by TTE and total EAT vol-
ume obtained by CMR in our center. Third, we did not report 
biological parameters such as insulin resistance index, serum 
triglyceride and cholesterol. This should be done in future 
studies to better characterize respective effects of obesity, 
the metabolic syndrome and type 2 diabetes on EAT.
Conclusions
Large EAT amounts are independently associated with more 
pronounced and severe LV remodeling AS. These new find-
ings combined with previous bench studies argue for EAT 
being a potential actor of cardiac remodeling in the context 
of chronic pressure overload.
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